Synoesis Therapeutics
SyNoesis Therapeutics is a start-up biotech with the vision to cure Parkinson’s disease (PD) and other major brain diseases. We aim to capitalize on the potential of a new therapeutic we have patented for PD to be further developed towards being successful in clinical trials and become the first drug to cure it.
TargED
TGD001 is a fusion protein with a vWF binding moeity linked to the catalytic domain of Urokinase. Once TGD001 binds to vWF present in all blood clots it will localy activate Plasminogen into Plasmin and Plasmin is known to cleave fibrin (tPA is a commercial available product that works with the same Mode of Action […]
AuraVax Therapeutics
AuraVax Therapeutics, Inc. (AuraVax) is a privately held biotechnology companycommercializing a new STING activation platform “NanoSTING” as an intranasal hostdirected-therapeutic for the treatment and prevention of upper respiratoryinfections (URI) independent of the infecting pathogen(s).
Cryptyx Bioscience
The Cryptyx Bioscience drug discovery platform provides a rapid, efficient approach for activating silent biosynthetic gene clusters and unearthing potential leads that cannot be accessed with extant technologies.
Nitro Bioscience
Nitro Biosciences is developing a next-generation antigen engineering platform to address issues of immune imprinting in vaccine development. The company is focused on applying its platform toward development of a lead candidate for a universal influenza vaccine.
Neurosov
NeuroSoV has developed a molecule for a specific identified target that, together with a patented reformulation technology, improves the bioavailability of the drug and prevents neurodegeneration in Parkinson’s context
HemostOD
HemostOD engineers and manufactures platelets to unlock their potential in indications such as thrombocytopenia, tissue-targeted cargo delivery, and regenerative medicine.
Fusix Biotech
Fusix Biotech develops a novel platform of cancer therapeutics that will revolutionize immune oncology
Refoxy Pharma
Refoxy Pharma is a pre-clinical stage biotechnology company developing medicines for the treatment and prevention of aging and aging-associated diseases. FOXO proteins are transcription factor proteins that bind to specific DNA sequences and thereby control (turn on/off) the expression of genes in those regions. This ability allows transcription factors to modulate different biological processes. Refoxy […]
Lys Therapeutics
Lys Therapeutics is a biotechnology company pioneering a breakthrough approach to treat patients suffering from neurodegenerative or neurovascular disorders. Its main drug is a first-in-class monoclonal antibody, Glunozumab, displaying an exclusive and groundbreaking mechanism of action.
